BiotechTube

Branaplam + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Early Manifest Huntington Disease

Conditions

Early Manifest Huntington Disease

Trial Timeline

Dec 8, 2021 → Oct 27, 2023

NCT ID
NCT05111249

About Branaplam + Placebo

Branaplam + Placebo is a phase 2 stage product being developed by Novartis for Early Manifest Huntington Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05111249. Target conditions include Early Manifest Huntington Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05111249Phase 2Terminated

Competing Products

20 competing products in Early Manifest Huntington Disease

See all competitors
ProductCompanyStageHype Score
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
25
Anastrozole + Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
Fezolinetant + PlaceboAstellas PharmaPhase 2
52
Lecanemab IV + Placebo + Lecanemab SCEisaiPhase 3
77
E2609EisaiPhase 1
33
Doxorubicin + Cyclophosphamide + Taxane + Letrozole + Abemaciclib + LHRH AnalogueEli LillyPhase 2
52
PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
77
ICGJohnson & JohnsonPre-clinical
23
SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
77
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
77
SHR7280 tabletsJiangsu Hengrui MedicinePhase 2
52
SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
77
Nab-paclitaxel in combination with pyrotinibJiangsu Hengrui MedicinePhase 2
52
Adalimumab + Methotrexate + Adalimumab placebo + Methotrexate placeboAbbViePhase 3
77
adalimumab + methotrexateAbbViePhase 3
77
Camizestrant + Tamoxifen + Anastrozole + Letrozole + ExemestaneAstraZenecaPhase 3
77
Camizestrant + Tamoxifen + Anastrozole + Letrozole + Exemestane + AbemaciclibAstraZenecaPhase 3
77
Tamoxifen alone + Tamoxifen + AminoglutethimideAstraZenecaPhase 3
77
Cyclophosphamide + Methotrexate + Fluorouracil implant + Goserelin + TamoxifenAstraZenecaPhase 3
77
Trastuzumab deruxtecan + Standard-of-CareAstraZenecaPhase 2
52

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85